Valproic acid exerts differential effects on CXCR4 expression in leukemic cells

Leukemia Research

Volumn 34, Issue 2, 2010, Pages 235-242

  Gul, Hilal ^a,b   Marquez Curtis, Leah A ^a   Jahroudi, Nadia ^b   Larratt, Loree M ^b   Janowska Wieczorek, Anna ^a,b  

^a CANADIAN BLOOD SERVICES   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

AML; Chemotaxis; HDAC inhibitors; SDF 1 CXCR4 axis; Valproic acid

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL MATURATION; CELL STRAIN HL 60; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALE; MONOCYTIC LEUKEMIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD34; CELL DIFFERENTIATION; CHEMOTAXIS; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; RECEPTORS, CXCR4; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 74849120227     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.05.014     Document Type: Article

References (46)

1. Kucia M., Reca R., Miekus K., et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23 (2005) 879-894
2. Broxmeyer H.E., Orschell C.M., Clapp D.W., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201 (2005) 1307-1318
3. Lapidot T., Dar A., and Kollet O. How do stem cells find their way home?. Blood 106 (2005) 1901-1910
4. Peled A., Kollet O., Ponomaryow T., et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 95 (2000) 3289-3296
5. Tavor S., Petit I., Porozov S., et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 64 (2004) 2817-2824
6. Mohle R., Schittenhelm M., Failenschmid C., et al. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol 110 (2000) 563-572
7. Spoo A.C., Lubbert M., Wierda W.G., et al. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 109 (2007) 786-791
8. Konoplev S., Rassidakis G.Z., Estey E., et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 109 (2007) 1152-1156
9. Burger J., and Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23 (2009) 43-52
10. Burger J.A., and Burkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 137 (2007) 288-296
11. Cheung P., Allis C.D., and Sassone-Corsi P. Signalling to chromatin through histone modifications. Cell 103 (2000) 263-271
12. Pazin M., and Kadonaga J. What's up and down with histone deacetylation and transcription. Cell 89 (1997) 325-328
13. Minucci S., Maccarana M., Cioe M., et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogeneic activation. Mol Cell 5 (2001) 811-820
14. Plass C., Oakes C., Blum W., and Marcucci G. Epigenetics in acute myeloid leukemia. Semin Oncol 35 (2008) 378-387
15. Ferrara F., Fazi F., Bianchini A., et al. Histone deacetylase-targeted treatment restores retinoic acid signalling and differentiation in acute myeloid leukemias. Cancer Res 61 (2001) 2-7
16. Warrell R., He L., Richon V., et al. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90 (1998) 1621-1625
17. Gurvich N., and Klein P.S. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther 96 (2002) 45-66
18. Gottlicher M., Minucci S., Zhu J., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20 (2001) 6969-6978
19. Kuendgen A., and Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 110 (2007) 943-954
20. Cimino G., Lo-Coco F., Fenu S., et al. Sequential valproic acid/All-trans Retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 66 (2006) 8903-8911
21. McMullin M.F., Nugent E., Thompson A., et al. Prolonged molecular remission in PML-RAR-alpha-positive acute promyelocytic leukemia receiving treatment with chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate. Leukemia 19 (2005) 1676-1677
22. Pilatrino C., Cilloni D., Messa E., et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 104 (2005) 101-109
23. Bug G., Ritter M., Wassmann B., et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 104 (2005) 2717-2725
24. Guel H., Wassmann B., Romanski A., et al. Effect of the histone deacetylase inhibitor valproic acid in combination with all-trans retinoic acid on normal and malignant hematopoiesis. Blood 102 (2003) 2313a
25. Bug G., Gul H., Schwarz K., et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 65 (2005) 2537-2541
26. De Felice L., Tatarelli C., Mascolo M.G., et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res 65 (2005) 1505-1513
27. Gul H, Marquez-Curtis L, Jahroudi N, et al. Valproic acid increases CXCR4 expression in hematopoietic stem/progenitor cells by chromatin remodelling. Stem Cells Dev 2009; 18 (6) (in press).
28. Janowska-Wieczorek A., Marquez L.A., Matsuzaki A., et al. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J Haematol 105 (1999) 402-411
29. Peng W., and Jahroudi N. The NFY transcription factor inhibits von Willebrand factor promoter activation in non-endothelial cells through recruitment of histone deacetylases. J Biol Chem 278 (2003) 8385-8394
30. Cheng Y.C., Lin H., Huang M.J., et al. Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia. Leukemia Res 31 (2007) 1403-1411
31. Gul H., Marquez-Curtis L., Lo J., et al. The potent deacetylase inhibitor Trichostatin A (TSA) increases CXCR4 expression in hematopoietic stem/progenitor cells by chromatin remodelling. Blood 112 (2008) 1196a
32. Mori T., Kim J., Yamano T., et al. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 65 (2005) 1800-1807
33. Crazzolara R., Johrer K., Johnstone R.W., et al. Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br J Haematol 119 (2002) 965-969
34. Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009 [epub ahead of print October 2008].
35. Andreeff M., Konoplev S., Wang R.Y., et al. Massive mobilization of AML cells into circulation by disruption of leukemia/stroma cell interactions using CXCR4 antagonist AMD3100: first evidence in patients and potential for abolishing bone marrow microenvironment-mediated resistance. Blood 108 (2006) 171a
36. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., and Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12 (2006) 1167-1174
37. Marquez-Curtis L.A., Dobrowsky A., Montano J., et al. Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures. Br J Haematol 115 (2001) 595-604
38. Denkers I.A., de Jong-deBoer T.J., Beelen R.H., Ossenkoppele G.J., and Langenhuijsen M.M. VLA molecule expression may be involved in the release of acute myeloid leukaemic cells from the bone marrow. Leukemia Res 16 (1992) 469-474
39. Mahlknecht U., and Schönbein C. Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells. Haematologica 93 (2008) 443-446
40. Liu L.T., Chang H.C., Chiang L.C., and Hung W.C. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 63 (2003) 3069-3072
41. Bug G., Schwarz K., Schoch C., et al. Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 92 (2007) 542-545
42. Burgess A.J., Pavey S., Warrener R., et al. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 60 (2001) 828-837
43. Carew J.S., Giles F.J., and Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269 (2008) 7-17
44. Tavor S., Eisenbach M., Jacob-Hirsch J., et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia 22 (2008) 2151-2158
45. Mariadason J., Corner G., and Augenlicht L. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 60 (2000) 4561-4572
46. Bernhard D., Loffler M., Hartmann B.L., et al. Interaction between dexamethasone and butyrate in apoptosis induction: non-additive in thymocytes and synergistic in a T cell-derived leukemia cell line. Cell Death Differ. 6 (1999) 609-617